Genovis to present data from mAbCHECK™ system on ASMS June 4.

Genovis will for the first time present data from the mAbCheck™ analytical
platform solution at the American Society for Mass Spectrometry conference,
ASMS, in St. Louis USA. The system is built on Genovis enzyme technology and
Capsenze’s unique liquid handling technology and integrated with state of the
art mass spectrometry technology from Bruker.
The automated mAbCHECK™ technology allows researchers within the biopharma
industry to rapidly obtain critical product quality data via a completely
automated workflow. Researchers will no longer have to do manual sample
handling, as every step will be handled automatically in very short time.

- We are exited to show data for the first time using the mAbCHECK™ technology,
which utilizes our enzymes in a completely new setting. This first application
proves that the system is able to rapidly generate important analytical results
to our customers developing monoclonal antibodies for therapeutic use. The
mAbCHECK platform will help us expand our customer base and the use of our
enzyme within biopharma process development. We plan to accelerate the
development of this technology and start beta testing together with customers
this fall, says Fredrik Olsson, CEO of Genovis.

Additional information about mAbCHECK:

The mAbCHECK system is designed to sample a bioreactor and automatically digest
and separate individual antibody subdomains for direct analysis by mass
spectrometry or other technologies. The system is built on the VersAFLo liquid
handling system from Capsenze adapted for use with Genovis enzyme. The first
data presented at ASMS will show rapid glycan analysis of monoclonal antibodies
and Fc-fusions proteins using Bruker UHR MaXis Mass Spectrometry. Glycan pattern
is an important quality attribute that developers and producers of therapeutic
antibodies need to monitor.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative
technologies that facilitate and enable development of new treatment methods and
diagnostics for customers in the medical device and pharmaceutical industries.
The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis
develops and sells unique enzymes in innovative product formats that facilitate
development and quality control of and biological drugs. GeccoDots uses
nanotechnology to produce a new type of contrast agent that is used in medical
imaging.

Genovis shares are listed on NASDAQ Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00

ABOUT BRUKER CORPORATION (NASDAQ: BRKR)

For more than 50 years, Bruker has enabled scientists to make breakthrough
discoveries and develop new applications that improve the quality of human
life.  Bruker’s high-performance scientific research instruments and high-value
analytical solutions enable scientists to explore life and materials at
molecular, cellular and microscopic levels.

In close cooperation with our customers, Bruker is enabling innovation,
productivity and customer success in life science molecular research, in applied
and pharma applications, in microscopy, nano-analysis and industrial
applications, as well as in cell biology, preclinical imaging, clinical
research, microbiology and molecular diagnostics.  For more information, please
visit:  http://www.bruker.com.

Media Contact: Tony Lewtas,  Bruker Daltonics Division,  T: +1 978 663 3660
ext.1212, E: tony.lewtas@bruker.com

Investor Contact:  Joshua Young,  Vice President of Investor Relations, Bruker
Corporation, T: +1 978 663 3660  ext.1479,  E: joshua.young@bruker.com

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.